scispace - formally typeset
Search or ask a question
Author

W. R. Kim

Bio: W. R. Kim is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Liver transplantation & Primary sclerosing cholangitis. The author has an hindex of 7, co-authored 13 publications receiving 2215 citations.

Papers
More filters
Journal ArticleDOI
TL;DR: The MELD scale is a reliable measure of mortality risk in patients with end-stage liver disease and suitable for use as a disease severity index to determine organ allocation priorities in patient groups with a broader range of disease severity and etiology.

1,452 citations

13 Feb 1997
TL;DR: A new model to estimate patient survival in PSC includes more reproducible variables (age, bilirubin, albumin, aspartate aminotransferase, and history of variceal bleeding), has accuracy comparable to previous models, and obviates the need for a liver biopsy.

302 citations

Journal ArticleDOI
TL;DR: The cost-effectiveness of interferon- treatment from the point of view of society was assessed by comparing the number of liver-related deaths, quality-adjusted survival, and costs among the treatment strategies.
Abstract: Background: Interferon-α is effective in only a small number of patients with chronic hepatitis C, although prolonged treatment may increase the response rate. There is concern that the expense of ...

155 citations

Journal ArticleDOI
TL;DR: Patients undergoing OLT for NASH may develop recurrent steatosis shortly after transplantation, with possible progression to steatohepatitis and fibrosis, and patients with endstage liver disease due to NASH should be considered good candidates for OLT.
Abstract: Patients with nonalcoholic steatohepatitis (NASH) may develop progressive liver dysfunction necessitating liver transplantation (OLT) We report the incidence of recurrent disease and outcome in patients undergoing OLT for NASH Patients transplanted for NASH were identified according to pretransplant and explant liver histology Patients with significant alcohol consumption were excluded Medical records were reviewed to extract pre- and posttransplant data, including sequential body weight, biochemistry, and graft histology Of 622 liver explants, eight patients had features consistent with NASH All patients were female with a median age of 58 Seven patients were diagnosed with NASH preoperatively, including three who had undergone jejunoileal bypass One patient was diagnosed as cryptogenic cirrhosis At a median of 15 months following OLT, all of the eight patients were alive with no graft failure Six patients developed persistent fatty infiltration in their graft, three of whom had accompanying hepatocellular degeneration, consistent with a diagnosis of recurrent NASH In two patients, transition from mild steatosis to steatohepatitis and early fibrosis was observed over one to two years The patients who did not develop recurrent steatosis had significant weight loss following transplantation, although the length of follow-up was relatively short Patients undergoing OLT for NASH may develop recurrent steatosis shortly after transplantation, with possible progression to steatohepatitis and fibrosis Although longer follow-up is necessary to determine the eventual prognosis related to the recurrent fat and fibrosis in the graft, patients with endstage liver disease due to NASH should be considered good candidates for OLT

154 citations

Journal ArticleDOI
TL;DR: In contrast to the Child‐Pugh classification, which was developed for advanced liver cirrhosis, the Mayo model provides valid survival information, particularly in patients early in the course of PSC.

127 citations


Cited by
More filters
01 Jan 2010
TL;DR: Since the publication of the American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) in 2005, new information has emerged that requires that the guidelines be updated.
Abstract: Since the publication of the American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) in 2005, new information has emerged that requires that the guidelines be updated. The full version of the new guidelines is available on the AASLD Web site at http://www.aasld.org/practiceguidelines/ Documents/Bookmarked%20Practice%20Guidelines/ HCCUpdate2010.pdf. Here, we briefly describe only new or changed recommendations.

6,642 citations

Journal ArticleDOI
TL;DR: The prevention of Cirrhosis can prevent the development of HCC and progression from chronic HCV infection to advanced fibrosis or cirrhosis may be prevented in 40% of patients who are sustained responders to new antiviral strategies, such as pegylated interferon and ribavirin.

5,557 citations

Journal ArticleDOI
TL;DR: The research agenda for the future includes establishing the role of insulin resistance and abnormal lipoprotein metabolism in NASH, determining the pathogenesis of cellular injury, defining predisposing genetic abnormalities, identifying better noninvasive predictors of disease, and defining effective therapy.

2,134 citations

Journal ArticleDOI
TL;DR: In conclusion, acetaminophen hepatotoxicity far exceeds other causes of acute liver failure in the United States, and education of patients, physicians, and pharmacies to limit high‐risk use settings is recommended.

1,705 citations